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Original Article
Introduction
Breast screening in the UK was introduced in 1988 as a result
of the conclusion by the Forrest report that mass screening
by mammography would lead to earlier detection of breast
cancer.1 At the time, evidence in the form of case control and
randomized studies suggested that mortality from breast cancer
could be reduced by mammographic screening. Since then,
screening centres and quality assurance mechanisms to
monitor and reset standards have been well established. The
natural next phase in the development of the screening
programme is to objectively evaluate whether it has achieved
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its primary objective, i.e. a reduction in mortality from breast
cancer. Although several randomized controlled trials reported
a beneficial effect of screening on reducing mortality from
breast cancer,2–11 a recent meta-analysis questioned the findings
of these trials.12 Without a demonstrable and objective benefit
from screening, the considerable and rising financial cost
would question the validity of continuing with a national
screening programme.
In this study, we examined data from patients diagnosed
and treated for primary invasive breast cancer at a district
general hospital, which is a designated Forrest Screening
Assessment Centre and a recognized “Calman-Hine” breast
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OBJECTIVES: Evidence obtained from several randomized control trials suggest that mortality from breast
cancer could be reduced by mammographic screening. However, a recent meta-analysis questioned the general
acceptance that screening for breast cancer is beneficial. The purpose of the study was to analyze prospectively
collected data from our unit and produce overall and comparative 5-year survival rates for screen-detected and
symptomatic breast cancer.
METHODS: Prospectively collected data on all patients diagnosed with invasive breast cancer between January
1993 and December 1994 (24 months), and monitored until the end of 1999, were collated and analyzed. Five-year
survival was estimated and broken down by age at diagnosis, tumour size, grade and nodal status. The overall
5-year survival for women with screen-detected cancers was compared with that for women with symptomatically
presenting cancers.
RESULTS: Between January 1993 and December 1994, 308 patients with invasive breast cancer were referred to
the unit (162 via the breast screening programme and 146 presenting symptomatically). The overall 5-year survival
was 85.5% (confidence interval [CI], 80.8–89.1). Small tumour size, low grade and negative nodal status
were associated with higher survival rates. Five-year survival of the screen-detected cancer patients (91.7%; CI,
85.8–95.2) was higher than that of patients presenting symptomatically (78.6%; CI, 70.6–84.6; p < 0.001).
CONCLUSIONS: These findings suggest that patients with screen-detected breast cancer may have better sur-
vival compared to those with symptomatically detected breast cancer. The results support the argument in favour
of a beneficial impact of breast screening programmes on patients’ survival.  [Asian J Surg 2003;26(2):101–7]
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unit. The purpose of the study was to analyze this unit’s
prospectively collected data and produce overall and
comparative 5-year survival rates for screen-detected and
symptomatic breast cancer.
Materials and methods
The study examined the data on the treatment outcomes of
patients presenting with both symptomatic and screen-
detected breast cancer who presented to a district general
hospital in the North of England between January 1993 and
December 1994. Breast screening based on national guidelines
had been established in this general hospital for over 10 years,
and data had been prospectively collected for referrals both
from screening and symptomatically presenting patients with
breast cancer. The hospital is also a designated Calman-Hine
Breast Cancer Assessment Centre serving the Tees Valley. The
patients included all those who presented to the Breast Unit
and to the Assessment Centre for the National Health Service
Breast Screening Programme (NHSBSP), which served two
Forrest Units in the southern part of the Northern Region of
England. Information relating to age at diagnosis, tumour
size, tumour grade and the axillary nodal status was
analyzed, and survival profiles relating to these characteristics
were produced. Cases were identified via the Micromed
Computerized Medical Audit System, and details of all patients
diagnosed with breast cancer between 1st January 1993 and
31st December 1994 were obtained. Details of patients who
died prior to the end of the study date (31st December 1999)
were obtained through collaboration with Northern and
Yorkshire Cancer Registry and Information Service (NYCRIS)
and local health authority Cancer Registration Departments
(Tees Health and Durham). Patients’ survival was confirmed
from their outpatient clinic follow-up notes or, if they did
not attend the outpatient clinic, from their general practi-
tioner. A precise cause of death was requested from the
Cancer Registry in order to identify those who died of breast
cancer.
Survival study eligibility
In total, details of 366 patients with breast cancer were recorded.
Of these, 308 (84.2%) were diagnosed with invasive or mixed
cancers, 35 (9.5%) were diagnosed with non-invasive ductal
carcinoma in situ (DCIS) and, for 23 cases (6.3%), invasive
status was unavailable because the patients were not treated
surgically. All cases of invasive breast cancer (n = 308)
were selected for entry into the survival analysis; of these, 162
(52.6%) were screen-detected and 146 (47.4%) were symptomatic
cancers. Patients presenting with DCIS, all of whom are still
alive, were not included in the study.
Survival analysis
The end of the study date was set at 31st December 1999, which
ensured a minimum follow-up period of 5 years. Data were
analyzed for survival with respect to age group, tumour size,
tumour grade and nodal status. Survival of women with screen-
detected cancers was compared with that of women with
symptomatic cancers. Breast cancer-specific survival analysis
using the Kaplan–Meier method13 was undertaken using the
Stata (version 6) statistical package (Stata Corporation, College
Station, TX, USA). The log-rank test was used to detect
differences between the groups with an accepted level of
significance of p < 0.05.
Study population characteristics
The characteristics of the 308 eligible patients were examined
in terms of age at diagnosis, tumour size, grade and nodal
status.
Age at diagnosis
The distribution of age at diagnosis is presented in Table 1.
Data were divided into cohorts to correspond to those used by
the NHSBSP, where data refer to patients over the age of
49 years. The total age range was 29 to 92 years, with a mean
age of 58 years. Overall, 56 (18.2%) patients were under 50
years of age at diagnosis, 52 (16.9%) were 50 to 54 years, 65
(21.1%) were 55 to 59 years, 88 (28.6%) were 60 to 64 years and
47 (15.2%) were 65 years or more of age. Comparison of the
two groups showed that the number of patients presenting
symptomatically decreased significantly once they reach
screening age.
Table 1. Distribution of cases by age at diagnosis (n = 308)
Age (years) BSP detected (%) Symptomatic (%) Total (%)
0–49 6 (1.9) 50 (16.2) 56 (18.2)
50–54 32 (10.4) 20 (6.5) 52 (16.9)
55–59 47 (15.2) 18 (5.8) 65 (21.1)
60–64 69 (22.4) 19 (6.2) 88 (28.6)
65 or above 8 (2.6) 39 (12.6) 47 (15.2)
BSP = Breast Screening Programme.
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two patients the cause of death was unknown but for the
purpose of this study assumed to be related to breast cancer.
The overall 5-year survival was 85.5% (confidence interval [CI],
80.8–89.1) (Figure 1).
Survival by age group
Analysis showed no clear pattern of survival related to age
group at the time of diagnosis (p = 0.23).
Survival by tumour size
Survival curves related to tumour size are shown in Figure 2.
Survival rates indicate a clear relationship between tumour
size and survival: 69% (95% CI, 46–84) for women with tumours
of diameter greater than 50 mm compared with 95% (95% CI,
72–99) when the tumour was less than 10 mm, (p = 0.01).
Table 2. Distribution of cases by tumour size (n = 308)
BSP detected (%) Symptomatic (%) Total (%)
< 10 mm 19 (83) 4 (17) 23 (7)
10–24 mm 101 (56) 81 (44) 182 (59)
25–50 mm 32 (38) 52 (62) 84 (28)
> 50 mm 10 (53) 9 (47) 19 (6)
BSP = Breast Screening Programme.
Tumour size
The distribution of cases by tumour size is shown in Table 2.
Overall, 23 (7%) tumours were less than 10 mm in diameter,
182 (59%) were 10 mm to 24 mm, 84 (28%) were 25 mm to
50 mm and 19 (6%) were 50 mm or more in diameter.
There was a significantly higher incidence of small-size
tumours (< 10 mm) in the screen-detected cancer group
than in the symptomatically detected group (p < 0.05). As the
aim of the NHSBSP is to detect small well-differentiated
cancers, it is interesting to see that 83% of the cancers
of less than 10 mm were detected via screening, whereas 62%
of those between 25 and 50 mm in diameter presented
symptomatically.
Tumour grade
Tumour grade is presented in Table 3. Overall, 122 (40%) of
invasive cancers were recorded as grade 1, 83 (27%) as grade 2
and 56 (18%) as grade 3; 47 were special types (tubular,
cribriform, or others). The majority of grade 1 cancers were
diagnosed via breast screening (64%), whereas 75% of grade 3
cancers presented symptomatically.
Nodal status
Nodal status is presented in Table 4. Overall, 190 (62%) patients
were recorded as being node negative and 91 (29%) node
positive. Nodal status was unavailable in 27 (9%) patients. By
comparison, the quoted national incidence of unknown nodal
status was reported as 39% in 1992 to 1993, 19% in 1996 to
1997 and 13% in 1997 to 1998.14 In the screen-detected cancers,
the incidence of positive nodal status was 24.7%  compared to
34.9% in the symptomatic cancers.
Results
Of the 308 patients analyzed, 41 (13.3%) (12 from the screen-
detected group and 29 from the symptomatic group) died and
267 (86.7%) were alive at the end of the study. The cause of
death in two patients was not related to breast cancer, and in
Table 3. Distribution of cases by tumour grade (n = 308)
BSP detected (%) Symptomatic (%) Total (%)
Grade 1 77 (64) 45 (36) 122 (40)
Grade 2 44 (53) 39 (47) 83 (27)
Grade 3 14 (25) 42 (75) 56 (18)
Special type 27 (57) 20 (43) 47 (15)
BSP = Breast Screening Programme.
Table 4. Distribution of cases by nodal status (n = 308)
BSP detected (%) Symptomatic (%) Total (%)
Negative 106 (56) 84 (44) 190 (62)
Positive 40 (44) 51 (56) 91 (29)
Unknown 16 (59) 11 (41) 27 (9)
BSP = Breast Screening Programme.
Figure 1. Kaplan-Meier crude survival estimate (%) at 5 years for
Teeside patients diagnosed between 1993 and 1994.
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Survival by tumour grade
Survival curves related to tumour grade are shown in Figure 3.
Survival rates were significantly influenced by tumour grade,
and 5-year survival for women with grade 1 tumours (97%, 95%
CI, 92–99) was significantly higher than for those with grade
3 tumours (70%, 95% CI, 62–80, p = 0.001).
Survival by nodal status
Survival curves related to nodal status are shown in Figure 4.
A clear trend in survival was observed for women with negative
node status, showing a significantly higher 5-year survival
than those with positive node status (p < 0.01).
Survival by screen-detected versus symptomatic cancers
Women with screen-detected breast cancers had better 5-year
survival (91.7%) when compared to those with symptomatically
presenting cancers (78.6%; p < 0.001) (Figure 5).
Discussion
The official national NHS figures quote crude 5-year survival
rates for the Northern and Yorkshire NHS region of 54% in the
deprived areas and 64% for the affluent areas.15 The finding in
this study of a crude 5-year survival of 85.5% represents a
significant regional improvement in 5-year survival of 17% to
31%. For four patients, the cause of death was not available,
and they were considered to have died of breast cancer, which
may have resulted in our survival figures being underestimated.
This improvement in survival may represent a national decline
in mortality from breast cancer over the respective period of
time. In the late 1980s, mortality from breast cancer in the UK
was reported to be the highest in Europe.16 However, over the
Figure 3. Kaplan-Meier crude survival estimates (%) at 5 years, by
tumour grade.
Figure 4. Kaplan-Meier crude survival estimates (%) at 5 years, by
nodal status.
Figure 5. Crude survival (%) at 5 years, by comparison between
Breast Screening Program-detected and symptomatic cancers.
Figure 2. Kaplan-Meier crude survival estimates (%) at 5 years, by
tumour size (mm).
past decade, breast cancer mortality rates sharply declined
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the reorganization of cancer treatment services with improved
methods of specialized treatment and better access to cancer
specialists or multidisciplinary teams.18 It is likely that the
introduction of breast screening programmes, wide use of
chemotherapy and tamoxifen, and changes in socioeconomic
trends are the most significant contributors to this decline in
mortality.
Information on cancer survival is invaluable for monitoring
the efficacy of the national breast cancer screening and
treatment programmes. Such information forms the basis
upon which strategic decisions concerning organization and
improvement in cancer services are taken by health service
planners. Indeed, survival after cancer treatment has been
identified as one of the high-level performance indicators in
clinical governance as indicated in the government’s paper
“A First Class Service” and the green paper “Our Healthier
Nation”.19 Survival information is also vital for clinicians and
for patients and their families, and can influence their choice
of treatment. The beneficial impact of the national screening
programme on the outcome of breast cancer has recently
become a subject of controversy.12 Randomized controlled
trials (RCTs) are the most reliable method to objectively evaluate
the impact of mammographic screening on breast cancer
survival. As the screening programme is now established, it has
become neither possible nor ethical to conduct an RCT to
evaluate the current effect of screening on survival. Hence, we
now have to rely on observational studies of survival rates to
provide a reliable source of information and trends relating to
the effect of breast screening. However, there is a lack of
outcome data currently available for breast cancer in the UK,
and these data may not be accurate even when available. In
addition, data from NHSBSP are also inherently deficient in
outcome information, since it was originally designed for
collection up to the point of treatment only. This inaccuracy
and lack of data may be a significant contributory factor to the
quoted low survival figures for breast cancer in the UK
compared with other European countries and the USA. The
findings from this study suggest that, when survival data are
complete and accurately collected, they reflect the actual and
better survival figures.
The difference between the nationally quoted survival
figures for the Northern region and the findings from this
study is striking. The South Durham and Teeside area has
been classified as a deprived area with a 5-year survival rate for
breast cancer of 54% compared to an overall survival of 64% for
the region.15 It has been suggested that patients presenting
with breast cancer in affluent neighbourhoods have better
survival than those from socioeconomically deprived areas
and that this is not related to the extent of disease at the time
of diagnosis.15,21 Survival for women diagnosed in Teeside
during 1993/94 was not dissimilar to that reported for England
and Wales in general (68% vs 66%, respectively). These findings
not only refute the previous suggestion, but also question the
accuracy of the published regional and national figures for
breast cancer survival.
It is apparent that the national UK survival data depend on
complete and accurate local survival data and cancer registry.
Cancer registries regularly provide data extracts to the office
for national statistics where data are collated and analyzed.
Systematic follow-up of cancer patients until death should be
a routine component of hospital accreditation, as it has been
in the USA for many years.22 The absence of such a system in
all but a few hospitals in the UK can result in patients being
lost to follow-up and can lead to bias in survival estimates. The
fact that cancer patients are often treated in more than one
hospital, and in some cases they move between regions, is
another complicating element. This necessitates the
deployment of adequate hospital information technology
systems that allow the data for individual patients to be
satisfactorily linked both regionally and nationally. Such a
system requires cancer registries that record relevant
information for all cancer patients living in a given region. It
will not only allow the survival of breast cancer patients to be
accurately monitored over long periods of time, but will also
allow comparison of hospital/region-specific survival rates.
The survival of cancer patients, as well as trends in cancer
survival over time, can then be compared between geographic
regions or social groups with data from population-based
cancer registries. Such registries will also be invaluable in
the evaluation of mass screening programmes and major
reorganization of cancer treatment services.
Criticism of the NHSBSP in terms of cost benefit to patients
has been voiced with the view that greater benefit would have
been derived from advancing chemotherapy treatment
compared with NHSBSP.23,24 This study provides an objective
data response to this criticism and suggests that screening
reduces the burden of breast cancer, thereby improving survival
and the quality of life of cancer patients. In addition, by
detecting early cancers, the patients are subjected to lesser
surgery, which in most cases is breast-conserving. Breast
conservation not only saves patients the need for further
reconstructive surgery, but is of immense psychological
importance to most patients. Moreover, by avoiding the need
for more complex reconstruction procedures, and in some
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cases, the need for chemotherapy, it may result in significant
financial savings. Another criticism of the apparent
effectiveness of breast screening is that it is simply reflecting
a lead-time bias, but the wide variance between 5-year sur-
vivals for screen-detected and symptomatic patients seems
to refute this.
The results of this study also confirm the importance of
accurate tumour staging for all women with breast cancer, and
show a significant survival advantage for those patients with
screen-detected breast cancer where the anticipated higher
incidence of small well-differentiated tumour is confirmed. It
is not clear whether the pathological entities of breast cancer
diagnosed via breast screening are different from those
diagnosed in symptomatic patients. Nonetheless, since the
clinical stage of disease at diagnosis is a key factor in the
outcome of treatment, breast screening, resulting in early and
prompt detection of breast cancer, is bound to offer obvious
prognostic benefits. For example, screening inevitably leads to
an increasing proportion of breast cancer being diagnosed
with a lower Nottingham prognostic index (i.e. good prognosis
group).25 First, screening leads to early detection of cancer
with an increased number of non-invasive and special types of
cancer. There is evidence to suggest that delay in cancer
presentation to provider services is associated with poorer
survival.26,27 Secondly, the national figures report a higher
incidence of small-sized tumours in screen-detected patients
compared to symptomatic patients, with the numbers of breast
cancers less than 15 mm in size constituting over 50% of the
screen-detected invasive cancers. In this study, the incidence of
breast cancer of less than 10 mm in size was 12% in screen-
detected cancers, but accounted for only 3% of symptomatic
cancers. The third key prognostic factor is the pathological
status of axillary lymph nodes. The incidence of positive nodes
in screen-detected breast cancer ranges from 15–25% compared
with 25–55% in symptomatically presenting disease.28
In conclusion, this study supports the argument in favour
of a beneficial impact of breast screening programmes on
patient survival. It also emphasizes the importance of accurate
data collection for regional comparisons of survival. However,
it may be that only 10-year figures show the impact of associated
improvements in oncological (non-surgical) intervention, if
any, and any hidden effect of lead-time bias.
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